IGXT News Alert Intelgenx Technologs (IGXT) 0.5400 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intelgenx Technologs (IGXT) 0.5400 $IGXT

IntelGenx Grants Stock Options
GlobeNewswire - Mon Dec 08, 1:54PM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company" (TSX-V:IGX) (OTC.QX:IGXT) announced today that the Company's board of directors granted options to acquire 175,000 common shares under the 2006 Stock Option Plan as amended. Of the total stock options granted, 25,000 were granted to each of the following non-employee directors Bernard Boudreau, Ian Troup and Bernd Melchers, 25,000 were granted to each of Horst G. Zerbe, the Chief Executive Officer and Paul A. Simmons, the Chief Financial Officer. Another 25,000 stock options were granted to each of two of the companies employees.
IGX.VN: 0.570 (unch)

IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)
GlobeNewswire - Tue Dec 02, 6:32AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its licensing partner Edgemont Pharmaceuticals, LLC ("Edgemont" has exercised its right to extend the license for the exclusive marketing of Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.570 (unch)

German regulator starts review of Rizaport MAA
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:43AM CST

RDHL: 12.22 (-0.13)

IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:03AM CST
-- The German Federal Institute for Drugs and Medical Devices ("BfArM" has validated the European Marketing Authorization Application submitted for RIZAPORT(TM) and initiated its formal review of the application on November 25, 2014
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)

RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:00AM CST
-- The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)

IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Wed Nov 26, 7:41AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.570 (unch)

IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Tue Nov 25, 7:08AM CST
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.570 (unch)

Stocks to watch ahead of the "Best of the Uncovereds" conference
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:45AM CST

ACET: 21.85 (-0.07), ACU: 18.57 (unch), BONE: 2.59 (-0.02), MNTX: 11.74 (-0.19), TREC: 15.19 (+0.52), INTL: 19.91 (-0.28), HPJ: 5.03 (+0.14), SPA: 28.20 (-0.41), AXPW: 1.00 (-0.04), ADES: 20.77 (+0.15), DXPE: 51.55 (-0.41), LODE: 0.69 (-0.02), LABL: 54.82 (-0.05), NEWT: 13.37 (-0.22), SA: 7.03 (+0.22), PSEC: 8.59 (-0.02)

IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference
GlobeNewswire - Tue Nov 18, 7:40AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time.
IGX.VN: 0.570 (unch)

IntelGenx reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:19AM CST


IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update
GlobeNewswire - Wed Nov 12, 7:02AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced financial results for the three and nine months ended September 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated.
IGX.VN: 0.570 (unch)

Small Cap Traders Delivers Brief Report: IntelGenx Technologies Corporation Targeting Better Outcomes
PR Newswire - Thu Nov 06, 6:00AM CST
Brief Analyst Report by Small Cap Traders. IntelGenx Technologies Corporation (OTCBB: IGXT) - According to a January 2014 report by BCCResearch, global revenues for advanced drug delivery systems in 2013 were an estimated $151.3 billion. Revenues for advanced drug delivery systems are estimated to grow by compound annual growth rate (CAGR) of 2.8% through 2018, reaching $173.8 billion. These targeted drug delivery systems are used to increase the concentration of medications in some parts of the human body relative to other parts. This reduces the frequency of drug dosages required by the patient, results in a more uniform effect from the drug, and lowers drug side-effects. One company involved in this industry is IntelGenx Technologies Corporation.

IntelGenx Announces Successful Clinical Study for Schizophrenia
GlobeNewswire - Mon Nov 03, 7:37AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company" today announced the successful completion of a pilot clinical study for INT0036 that demonstrated a significantly improved pharmacokinetic profile against the reference product. INT0036 is indicated for the treatment of schizophrenia and utilizes the Company's proprietary VersaFilm(TM) technology.
IGX.VN: 0.570 (unch)

This Small Cap Is Poised To Tap Multi-Billion Dollar Migraine Treatment Market
Tedra DeSue - at Seeking Alpha - Thu Oct 16, 8:14AM CDT

RDHL: 12.22 (-0.13)

IntelGenx Founder Returns as President and CEO
GlobeNewswire - Thu Oct 02, 7:02AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its board of directors unanimously decided to appoint the company's founder, Dr. Horst G. Zerbe, as President and Chief Executive Officer. Dr. Zerbe led the company in the same roles from April 2006 to December 2013 and also has been serving as interim President and CEO since July 2014.
IGX.VN: 0.570 (unch)

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R) (formerly RHB-103)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focused on oral drug delivery, that they have submitted a Marketing Authorization Application ("MAA" to the German Federal Institute for Drugs and Medical Devices ("BfArM" seeking European marketing approval of RHB-103, an oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT. The brand name RIZAPORT for RHB-103 was also conditionally approved by the U.S. Food and Drug Administration ("FDA" as part of the New Drug Application ("NDA" review process in the U.S., subject to a Complete Response Letter ("CRL" received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focused on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, that they have submitted a Marketing Authorization Application ("MAA" to the German Federal Institute for Drugs and Medical Devices ("BfArM" seeking European marketing approval of their oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT(R). The brand name RIZAPORT(R) was also conditionally approved by the U.S. Food and Drug Administration ("FDA" as part of the New Drug Application ("NDA" review process in the U.S., subject to a Complete Response Letter ("CRL" received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)

IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference
GlobeNewswire - Wed Sep 17, 8:28AM CDT
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research 9th Annual Best of the Uncovereds Conference to be held Monday, September 22, 2014 at the Luxe Hotel in Los Angeles, California. IntelGenx' presentation will take place September 22, 2014 at 9:30 AM Pacific Time.
IGX.VN: 0.570 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 46

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Cruise Line Celebrates Employees as Godparents of Treasure

Updated Category News Views 97

Disney Cruise Line Celebrates Employees in Honor of Disney Treasure Disney Cruise Line is redefining maritime traditions in a beautiful manner by honoring its dedicated employees worldwide. The company’s latest announcement revealed that the honorific role of "godparent" for the new ship, the Disney Treasure, will be shared among its tremendous cast, crew, Imagineers,...

Continue Reading
Regional Management Corp. to Share Q3 2024 Financial Insights

Updated Category News Views 79

Regional Management Corp. to Announce Q3 Results Greenville, S.C. – Regional Management Corp. (NYSE: RM), a prominent player in the consumer finance sector, is set to share its financial results for the third quarter of 2024. Conference Call Details and Replay The company will report its quarterly results after market close, providing investors and stakeholders with...

Continue Reading
Suvoda Recognized as a Leader in Clinical Trial Technology

Updated Category News Views 147

Suvoda Acknowledged as a Leader in RTSM Technology Suvoda, a cutting-edge clinical trial technology company, recently shared exciting news about their IRT (Interactive Response Technology) software, which has been designated as a Leader in the prominent Everest Group's PEAK Matrix assessment for RTSM (Randomization and Trial Supply Management) technology. This recognition...

Continue Reading
Cereno Scientific Expands CS014 Focus to Combat PH-ILD

Updated Category News Views 131

Cereno Scientific Expands CS014 Focus to Combat PH-ILD Cereno Scientific, a pioneering biotech company, has made a significant announcement regarding the development focus of its HDAC inhibitor CS014. This innovative treatment is now targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), an area marked by a high level of unmet medical need....

Continue Reading
Dysmenorrhea Treatment Market Growth Insights for 2032

Updated Category News Views 188

Global Dysmenorrhea Treatment Market Insights Dysmenorrhea, commonly referred to as menstrual cramps, affects many women globally, causing significant discomfort during their menstrual cycles. Recent trends indicate that as awareness of this condition grows, so does the demand for effective treatments. The global dysmenorrhea treatment market is projected to surpass USD 8...

Continue Reading